Axxam

What is Axxam?

Axxam is an innovative Partner Research Organization (iPRO) that serves as a trusted partner in science, focusing on the translation of innovative biology into bioactive molecules. Established in 2011 and headquartered in Milan, Lombardia, Axxam specializes in the development of small molecule drugs that directly target inflammation. They support pharmaceutical and biotech companies, start-ups, patient foundations, and academic groups in advancing from hit identification to lead generation across a variety of therapeutic areas and target classes.

Axxam's team of experienced scientists offers services for the identification and validation of bioactive molecules within life sciences industries. They apply their science-driven approach to discover new compounds for various sectors, including crop protection, animal health, and the creation of new flavors, fragrances, and taste modulating ingredients for the food, beverage, pet food, cosmetics, and perfume industries.

Their commitment to quality and innovation is evident in their receipt of various certifications, such as the EcoVadis Silver Medal for sustainability and corporate responsibility, Gender Equality certification, UNI EN ISO 9001:2015 for quality management systems, and UNI CEI EN ISO/IEC 27001:2024 for information security management systems.

Axxam also participates in research and developments projects such as Q-RARE, co-financed by the European Union, which focuses on rare diseases and conditions with high unmet treatment needs.

Their unique approach to drug discovery, characterized by a combination of cutting-edge science and teamwork, strives for high-quality results and client satisfaction. Axxam's services also include In Vitro Assays, Hit & Lead Discovery, Screening Collections, Biological Platforms, and Integrated Drug Discovery, demonstrating their comprehensive model for partnering with clients in the scientific community.